Update on the use of etanercept across a spectrum of rheumatoid disorders
Bernard CombeService d’Immuno-Rhumatologie, Montpellier, FranceAbstract: Etanercept is a soluble TNF receptor p75 fusion protein which is approved for subcutaneous use (50 mg weekly) in the treatment of patients with active rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2008
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/34d4e5cc2b404c0888c6180605d3f83d |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|